Photobiomodulation Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Photobiomodulation (PBM), also known as low-level laser therapy (LLLT) or phototherapy, is a non-invasive therapeutic approach that uses specific wavelengths of light (typically red 600-700 nm and near-infrared 770-880 nm) to stimulate cellular metabolism, reduce inflammation, and promote tissue repair. This emerging therapy shows promise for Alzheimer's Disease (AD), Parkinson's Disease (PD), traumatic brain injury (TBI), and other neurodegenerative conditions.
- NIR light absorbs to cytochrome c oxidase (COX) in mitochondrial Complex IV
- Enhances electron transport and ATP production
- Increases cellular energy available for repair processes
- Increased ATP production: Up to 300% in some studies
- Reduced ROS: Paradoxical reduction in reactive oxygen species
- Improved mitochondrial membrane potential
- Enhanced mitophagy: Clearance of damaged mitochondria
- Increased cAMP: Secondary messenger signaling
- Calcium homeostasis: Modulates intracellular calcium
- NF-κB pathway modulation: Anti-inflammatory effects
- BDNF expression: Neurotrophic factor upregulation
- Microglial modulation: Shift from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype
- Reduced TNF-α and IL-1β: Pro-inflammatory cytokines
- Increased anti-inflammatory cytokines: IL-10, TGF-β
¶ Neurogenesis and Synaptic Plasticity
- Enhanced hippocampal neurogenesis
- Improved synaptic function: Increased synaptophysin
- Angiogenesis: New blood vessel formation
- Temporary BBB opening: Enhanced drug delivery
- Improved cerebral blood flow
- Reduced amyloid burden in AD models
- Transcranial PBM improves cognition in mild to moderate AD
- Reduced amyloid plaques in animal models
- Improved cerebral blood flow
- May slow disease progression
- Home use devices showing promise
- Neuroprotective effects in MPTP models
- Reduced dopaminergic neuron loss
- Improved motor function in clinical studies
- Combined with L-DOPA may allow dose reduction
- May reduce Lewy body pathology
- Reduced neuroinflammation
- Improved cognitive recovery
- Enhanced functional outcomes
- FDA-approved for TBI
- Improved motor recovery
- Reduced inflammation
- Enhanced neuroplasticity
¶ Depression and Anxiety
- Modulates prefrontal cortex activity
- May reduce treatment-resistant depression
- Anxiolytic effects observed
| Parameter |
Recommended Range |
| Wavelength |
630-670 nm (red) or 810-904 nm (NIR) |
| Power density |
1-100 mW/cm² |
| Energy density |
1-10 J/cm² per site |
| Treatment duration |
10-30 minutes |
| Sessions |
2-3x per week for 4-12 weeks |
- Transcranial: External head application
- Intranasal: Light delivery to brain via nasal passages
- Wearable devices: Helmets, headbands
- Epidranial: Surgical implantation for targeted delivery
- Systemic: Illuminating blood ex vivo and returning to body
- Prefrontal cortex
- Temporal regions
- Motor cortex
- Hippocampus (indirectly via temporal)
- Systemic (intravenous)
- Non-invasive
- Minimal side effects
- Can be self-administered with home devices
- Cost-effective
- No drug interactions
- Alzheimer's disease (mild to moderate)
- Parkinson's disease
- Traumatic brain injury
- Post-stroke recovery
- Age-related cognitive decline
- Depression/anxiety
- Active cancer (may stimulate growth)
- Photosensitivity disorders
- Epilepsy (certain frequencies)
- Pregnancy
- Active infection
- Generally very safe
- Mild headache reported
- Eye protection required
- Not for use over tumors or implants
- Optimal parameter determination (wavelength, dose, frequency)
- Biomarker development for treatment response
- Combination with other therapies
- Home device optimization
- Large-scale clinical trials
- Gene expression studies
The study of Photobiomodulation Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hamblin MR. Photobiomodulation for Alzheimer's disease: Has the time come? J Alzheimers Dis. 2021;80(4):S283-S294.
- Salehpour F, et al. Photobiomodulation therapy improves Alzheimer's disease: Animal and clinical evidence. Ageing Res Rev. 2020;62:101095.
- Johnstone DM, et al. Turning on lights to stop neurodegeneration: The potential of near infrared light therapy in Alzheimer's and Parkinson's disease. Front Neurosci. 2016;9:500.
- Oron A, et al. Low-level laser therapy for Alzheimer's disease. J Alzheimers Dis. 2020;76(3):909-917.
- Santos L, et al. Neuroprotective effects of photobiomodulation in Parkinson's disease models. Sci Rep. 2020;10(1):20209.